Clinical Trial

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label, multicenter,study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant - Page 1 of 5 - protein) combine with IMM27M(Anti-CTLA-4 Humanized monoclonal antibody) in patients with advanced hepatocellular carcinoma who not have received the treatment for aHCC in past
Trial Details
NCT Number NCT07687914
Lead Sponsor ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions HCC - Hepatocellular Carcinoma
Enrollment 50 participants
Start Date 2026-07-23
Primary Completion 2027-07-23 (estimated)
Study Completion 2028-07-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-07